BioCentury
ARTICLE | Clinical News

AeroVanc: Phase II started

April 29, 2013 7:00 AM UTC

Savara began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily 32 and 64 mg AeroVanc for 28 days in about 80 patients. Patients with co-infected with Pseudomonas aerugino...